FRANKFURT (Reuters) - Bayer announced a collaboration deal with Roche's Foundation Medicine Inc. to develop a test for sequencing tumour genomes to identify patients who can benefit from Bayer's ...

Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges ...

Among the potential blockbusters that could save the day for Bayer when top-selling meds Eylea and Xarelto fall off the patent cliff, the German company is touting one simply as “the kidney medicine.” ...

Bayer has teamed up with Foundation Medicine to develop genetic diagnostic tests for several of its cancer therapies—starting with the tissue-agnostic Vitrakvi in solid tumors with TRK fusion ...

The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...

IONIS-FXI-LRx, Ionis' first-in-class FXI anti-thromboticmedicine, to potentially treat millions of patients globally Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics ...

Union City Commissioner Douglas Bine filed the suit in November of 2024 after losing his seat in a close election. New report reveals families in southern Ohio living on land at risk of causing cancer ...

WHIPPANY, N.J. & CHICAGO--(BUSINESS WIRE)--Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic ...

Bayer's stock slumped about 10 percent in midday trading Monday - the most in almost seven years - three days after a California jury awarded $289 million to a former groundskeeper who said the ...